ACCCBUZZ BLOG

ACCC is committed to helping cancer care team members, patients, and caregivers understand how bispecific antibody treatments fit within the cancer care continuum, how they differ from CAR T-cell therapy, and the education and resources available to patients and their families.

The first facility on Long Island, NY to offer next-generation sequencing with point-of-care genomic testing opened this May, and brought access to state of the art medical technology to patients in 6 different counties in the region.

Explore the role of cardio-oncology in understanding and managing potential cardiovascular complications of immune checkpoint inhibitors.

ACCCBuzz recognizes June as Cancer Immunotherapy Month.

Explore insights from this LinkedIn Live event highlighting the crucial role of pathologists within the multidisciplinary cancer care team.

ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.

Highlights from a LUNGevity Lung Cancer Precision Medicine Summit that addressed critical issues surrounding biomarker testing in non-small cell lung cancer.

LUNGevity invited ACCC and other stakeholders across the oncology world to Washington DC, for their second Health Equity Summit on Tuesday, March 12.

ACCC, ACS CAN, and LUNGevity, launched a series of focus groups earlier this year aimed at making the case for increasing access to comprehensive genomic profiling for Medicaid beneficiaries.

ACCC has developed an initiative to support health care providers in applying evidence-based treatment selection for patients with advanced/metastatic gastric cancer. Learn more.

At the ACCC 40th NOC, an exclusive EHR Working Summit was held to understand and explore effective practices/workaround solutions for streamlined biomarker test ordering and results management.

As CAR T-cell therapies provide new treatment options for patients with certain hematologic malignancies, it is important that more cancer centers and programs deliver them.

Key takeaways from day 1 of #ACCCNOC.

Through a series of education projects, ACCC is committed to providing the resources the multidisciplinary cancer care team will need to navigate the complex precision medicine landscape and deliver next generation cancer care.

As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.

In the era of personalized medicine, biomarker testing is a tool the oncology workforce can and should leverage to deliver next generation cancer care.

Managing immunotherapy related adverse events (irAEs) requires a team-based effort, with pharmacists playing an integral role in their identification and management within both outpatient and inpatient multidisciplinary teams.

In the past, patients diagnosed with rare cancer types often faced a bleak prognosis due to limited treatment options. Today, the story is different, as advances in precision medicine and the development of new, targeted therapies continue to permeate the oncology space.

June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.

ACCCBuzz spoke with Luis E. Raez, MD, FACP, FCCP, to learn more about the importance of closing the gap in access to biomarker testing and strategies to improve equity and inclusion in precision medicine.

March is Multiple Myeloma Awareness Month. Learn more about the work ACCC is doing to support oncology professionals in treating patients with this disease.

With the variety of models and titles that have emerged under precision medicine stewardship, learn how one cancer program is breaking down the this complex landscape into streamlined workflows to improve efficiency and better support growing test volumes.

Before opening the ACCC 49th Annual Meeting & Cancer Center Business Summit to its membership, ACCC held two pre-conference events on Wednesday, March 8. Learn more about what was discussed among invited speakers during these events.

ACCC President Dr. David R. Penberthy's final Tech Talk featured 4 panelists, who shared their perspectives on how technologies like artificial intelligence, machine learning, and the use of big data are currently impacting cancer care delivery, as well as their vision of the ideal future state.

Dr. Kevin Davies previews his opening keynote at the upcoming Association of Community Cancer Centers (ACCC) 49th Annual Meeting & Cancer Center Business Summit (AMCCBS).

As the director of Oncology Supportive Services at M Health Fairview, Jeff Kendall Psy D, LP has spearheaded the implementation of an electronic patient-reported outcomes program that will give healthcare providers an unprecedented insight on the symptoms patients may be experiencing.

The first post in ACCC's Subspeciality Immuno-Oncology Insights series—the APP perspective and real-world strategies for tackling current challenges in the delivery of immunotherapies for cancer.

ACCC shares how a precision medicine steward—a dedicated navigator focused specifically on biopsy samples and biomarker testing processes and results—can make a daunting biomarker testing process incredibly efficient for cancer programs and practices everywhere.

Dr. John Strickler from Duke Cancer Institute sat down with ACCCBuzz to talk about molecular profiling and data, including the cancer institute's own journey in oncology precision medicine.

Introduced in 2021, the Cancer Patient Equity Act seeks to provide coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program, and more.